Jeffrey Ding

Title: The Innovative Contributions of Jeffrey Ding

Introduction

Jeffrey Ding is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of insulin products. His work has implications for diabetes treatment and showcases the importance of innovation in pharmaceutical sciences.

Latest Patents

Jeffrey Ding holds a patent for a novel pro-insulin aspart structure and a method for preparing insulin aspart. This patent outlines a method that includes designing the pro-insulin aspart sequence, constructing recombinant insulin aspart engineered bacteria, and inducing the expression of an insulin fusion protein. The process involves extracting the insulin fusion protein through denaturing, renaturing enzymatic digestion, and separation purification operations. By modifying the recombinant leading peptide and C-peptide sequences, his method eliminates the need for a cyanogen bromide cleavage step, enhancing the efficiency of insulin production.

Career Highlights

Ding is currently associated with Amphastar Nanjing Pharmaceuticals Inc., where he continues to advance his research and development efforts. His innovative approach to insulin production has the potential to improve the quality and efficacy of diabetes treatments.

Collaborations

Some of his notable coworkers include Chuangen Tang and Shangshu Pan, who contribute to the collaborative environment that fosters innovation at Amphastar Nanjing Pharmaceuticals Inc.

Conclusion

Jeffrey Ding's work exemplifies the critical role of inventors in advancing medical technology. His contributions to insulin production not only highlight his innovative spirit but also reflect the ongoing need for research in the pharmaceutical industry.